Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: A systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2098-2110

  Costa, João ^a,b,c   Magro, Fernando ^d,e,f   Caldeira, Daniel ^b   Alarcão, Joana ^a,b   Sousa, Rita ^a   Vaz Carneiro, António ^a,c  

^a Evidence Based Medicine Centre   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c Iberoamerican Cochrane Network   (Portugal)

^d University of Porto   (Portugal)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

Biologic therapies; Hospitalization; Inflammatory bowel disease; Meta analysis; Operative; Surgical procedures; Systematic review

Indexed keywords

INFLIXIMAB;

CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; META-ANALYSIS AS TOPIC; PROGNOSIS; REVIEW LITERATURE AS TOPIC;

EID: 84884577666     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829936c2     Document Type: Review

References (65)

1. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;CD006893.
2. Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110.
3. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659.
4. Bernstein CN, Loftus EV Jr, Ng SC, et al; Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn's disease. Gut. 2012;61:622-629.
5. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641-6647.
6. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319-328.
7. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688.
8. Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010; 7:79-85.
9. Danese S, Colombel JF, Reinisch W, et al. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011;33:857-869.
10. Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011;60:1754-1763.
11. Feagan BG, Lémann M, Befrits R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis. 2012;18:152-160.
12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700. doi: 10.1136/bmj.b2700.
14. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
15. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331-2339.
16. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063.
17. Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2404-2413.
18. Wong WC, Cheung CS, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol. 2008;5:23.
19. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18: 800-804.
20. Caldeira D, Alarcão J, Vaz-Carneiro A, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345: e4260.
21. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed November 30, 2012.
22. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London, United Kingdom: BMJ Publication Group; 2001:313-335.
23. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575-1600.
24. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ. 1999; 318:1548-1551.
25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
26. Lémann M, Mary JY, Duclos B, et al; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130: 1054-1061.
27. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
28. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
29. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
30. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.
31. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
32. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology. 2005;128:1805-1811.
33. Gustavsson A, Järnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010;32: 984-989.
34. Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004;8: 231-233.
35. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
36. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260.
37. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
38. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.
39. Leombruno JP, Nguyen GC, Grootendorst P, et al. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011;20: 838-848.
40. Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Adv Ther. 2011;28:671-683.
41. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009;26:936-946.
42. Loomes DE, Teshima C, Jacobs P, et al. Health care resource use and costs in Crohn's disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497-502.
43. Waters HC, Vanderpoel JE, Nejadnik B, et al. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. J Med Econ. 2012;15:45-52.
44. Riis A, Martinsen TC, Waldum HL, et al. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol. 2012;47:649-657.
45. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther. 2010;32:1357-1363.
46. Thompson H, Pesa J, Zhao N, et al. Maintenance therapy with infliximab reduces hospitalization and surgery in Crohn's disease. Am J Gastroenterol. 2007;102(suppl 2):S436.
47. Uchino M, Ikeuchi H, Bando T, et al. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease. World J Gastroenterol. 2011;17:1174-1179.
48. Wheeler CD, Chipperfield R, Orchard T, et al. Infliximab reduces rates of emergency hospital admissions and surgical procedures: a UK retrospective study of Crohn's disease patients. Gut. 2012;61:A174.
49. Williams JB, Weber LR, Beaulieu DB, et al. Long-term infliximab maintenance infusion regimens and rates of hospitalization, surgery, and disability in Crohn's disease. Gastroenterology. 2006;130(4 suppl 2):A-143.
50. Bordeianou L, Kunitake H, Shellito P, et al. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis. 2010;25:401-404.
51. Ananthakrishnan AN, Issa M, Beaulieu DB, et al. History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:176-181.
52. Carter CT, Leher H, Smith P, et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care. 2011;17:385-392.
53. Desmond AN, Shanahan F. Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Ir J Med Sci. 2012;181:65-71.
54. Garcia-Planella E, Mañosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012;44: 206-210.
55. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18: 212-218.
56. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985;88:1818-1825.
57. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12.
58. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471-1478.
59. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics. 2002; 20:639-652.
60. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000;95:1955-1960.
61. Odes S, Vardi H, Friger M, et al; European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
62. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005;365:82-93.
63. Gartlehner G, Thieda P, Hansen RA, et al. Inadequate reporting of trials compromises the applicability of systematic reviews. Int J Technol Assess Health Care. 2009;25:323-330.
64. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011;8:e1001026.
65. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med. 2005;142:1090-1099.